Gilead Sciences has launched two Phase III clinical trials of its investigational antiviral drug remdesivir in the UK to treat Covid-19 patients.
The two studies will be conducted at 15 sites in the country, primarily in England and Scotland. One of the trials will involve patients with moderate symptoms and the other will enrol patients in a serious condition.
Gilead Sciences UK & Ireland vice-president and general manager Hilary Hutton-Squire said: “Gilead started research into remdesivir more than a decade ago.
We are now in a position to consider its potential to treat Covid-19 and rapidly progress its development and these clinical trials will help generate important data on the safety and efficacy of the medication in the coming